30 years later: the first person whom the cord blood was transplanted told about life after the transplantation.

2018-10-06

30 years later: the first person whom the cord blood was transplanted told about life after the transplantation.

Matthew Ferrow, who at the age of 6 was diagnosed with a hereditary disease of Fanconi anemia, today lives a full life, happily married and raising two children.

It all began in 1988 in Paris, when Elian Gluckman, a professor with Ukrainian roots, carried out Matthew the world's first transplantation of hematopoietic stem cells (HSC) of umbilical cord blood of his newborn sister. The procedure was successful and marked the beginning of an active study by scientists of the properties of cord blood stem cells.

After complete recovery, Matthew Ferrow undertook the mission of informing families around the world about the value of cord blood. Matthew, who now lives in the United States, believes that the main problem in most countries is the low awareness of doctors and future parents about the value of this biomaterial and makes every effort to popularize the topic of cord blood banking.

“Unfortunately, not many doctors talk about the possibilities of umbilical cord blood for the future protection of the family. I believe that we must change the situation by informing the public about every transplant and life saved, ”concludes Ferrow.

Already in 1988 it became obvious that the use of cord blood for the treatment of a number of serious diseases is very effective. Today, such transplants are estimated at thousands per year worldwide. Hematopoietic stem cells of cord blood are widely used in transplantology and are used to treat various diseases: blood diseases, including hematologic diseases, the immune system, a number of hereditary diseases, and are also being studied in the treatment of cerebral palsy, autism, diabetes and multiple sclerosis.

HEMAFUND works according to the most modern methods of cord blood processing, which guarantees the bank’s clients the maximum number of viable stem cells from each sample. Such material can be applied for treatment in any medical institution of Ukraine and of the world.